EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, APRIL 16, 2015
Media Advisory: To contact corresponding author Rowan T. Chlebowski, M.D., Ph.D., call Laura Mecoy at 310-546-5860 or email Lmecoy@labiomed.org. To contact corresponding editorial author Rama Khokha, Ph.D., call Jane Finlayson at 416-946-2846 or email firstname.lastname@example.org.
To place an electronic embedded link in your story: Links will be live at the embargo time: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.0494 and http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.0512
Analysis of the longer-term influence of menopausal hormone therapy on breast cancer incidence in two Women’s Health Initiative (WHI) clinical trials suggests a pattern of changing influences over time on breast cancer, according to an article published online by JAMA Oncology.
Use of menopausal hormone therapy decreased dramatically after reports of increased breast cancer risk with estrogen plus progestin from the WHI randomized clinical trial followed by the Million Women Study observational analysis. Following the initial WHI reports, decreases in both combined estrogen plus progestin use as well as estrogen alone use were seen. However, in the WHI randomized trials, while estrogen plus progestin increased breast cancer incidence and breast cancer deaths, estrogen alone in women with prior hysterectomy significantly reduced breast cancer incidence and breast cancer deaths. Those results raised questions about the short- and long-term postintervention effects of these two regimens on breast cancer.
Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, Calif., and coauthors examined early and late postintervention effects on breast cancer in the two WHI hormone therapy trials with a current median follow-up of 13 years.
A total of 16,608 women with a uterus were assigned to receive oral conjugated equine estrogens (0.625 mg/d [estrogen]) plus medroxyprogesterone acetate (2.5 mg/d [progestin]) or placebo with a median intervention of 5.6 years, and 10,739 women with prior hysterectomy were assigned to receive the estrogen alone or placebo with a median intervention of 7.2 years.
In the estrogen plus progestin trial, the increasing breast cancer risk seen during the intervention while women were receiving the combined hormones was followed by a substantial drop in risk in the early postintervention period (within 2.75 years from intervention) when hormone therapy was discontinued but a sustained higher breast cancer risk remained during the late postintervention period years after the therapy was stopped, according to the results.
In the estrogen alone trial, the reduced breast cancer risk seen during the intervention when women were receiving the estrogen lasted through the early postintervention phase but was lost during the late postintervention follow-up, the results show.
“The ongoing influences on breast cancer after stopping hormone therapy in the WHI trials require recalibration of breast cancer risk and benefit calculation for both regimens, with greater adverse influence for estrogen and progestin use and somewhat greater benefit for use of estrogen alone,” the article concludes.
(JAMA Oncol. Published online April 16, 2015. doi:10.1001/jamaoncol.2015.0494. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: An author made conflict of interest disclosures. The authors made funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Progesterone Exposure and Breast Cancer Risk
In a related editorial, Rama Khokha, Ph.D., of the Princess Margaret Cancer Centre, Toronto, Canada, and coauthors write: “Emerging detailed analyses from the WHI trials such as that reported by Chlebowski et al reveal new compelling evidence for the significance of progesterone in breast cancer where it has traditionally taken a back seat to estrogen. … Although the WHI trials relate to the menopausal setting, lessons learned from them continue to provide additional value in appreciating a potential role of progesterone even in premenopausal breast cancer. Furthermore, investigation into the cellular and mechanistic underpinnings of progesterone’s impact on the normal breast and breast cancer may provide new opportunities for knowledge translation and therapeutic intervention in breast cancer.”
(JAMA Oncol. Published online April 16, 2015. doi:10.1001/jamaoncol.2015.0512. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Authors made funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.